Potential for noninvasive brain tumor treatmentJune 17, 2009DURHAM, N.C. -- Duke University engineers have taken a first step toward a minimally invasive treatment of brain tumors by combining chemotherapy with heat administered from the end of a catheter. The proof-of-concept study demonstrated that it should be technically possible to treat brain tumors without the side effects associated with the traditional approaches of surgery, systemic chemotherapy or radiation. The bioengineers designed and built an ultrasound catheter that can fit into large blood vessels of the brain and perform two essential functions: provide real-time moving 3-D images and generate localized temperature increases. The researchers envision using this system in conjunction with chemotherapy drugs encased in heat-sensitive microbubbles called liposomes. "Physicians would inject drug-carrying liposomes into a patient's bloodstream, and then insert a catheter via a blood vessel to the site of the brain tumor," said Carl Herickhoff, fourth-year graduate student at Duke's Pratt School of Engineering and first author of a paper appearing in the journal Ultrasonic Imaging. "The catheter would use ultrasound to first image the tumor, and then direct a higher-power beam to generate heat at the site, melting the liposome shells and releasing the chemotherapy directly to the tumor. "The temperature increase would be about four degrees Celsius - enough to melt the liposome, but not enough to damage surrounding tissue," Herickhoff said. "No one has tried this approach before in the brain." The American Cancer Society estimates that more than 21,000 new brain tumor cases were diagnosed in 2008, with more than 13,000 patients dying. This represents about two percent of all cancer deaths. The researchers said that a minimally invasive approach to treating this cancer would be preferable to the conventional methods, which have drawbacks and side effects of their own. "Surgery is invasive, and chemotherapy that is injected or taken orally affects the whole body and has difficulty crossing the blood-brain barrier in sufficient concentrations," Herickhoff said. The blood-brain barrier restricts the passage into the brain of any foreign matter not needed by the neural tissue. In a series of experiments in animal models and simulated tissues, the researchers demonstrated that they could build a catheter thin enough to be placed in one of the brain's main blood vessels that was capable of serving the dual purpose of visualization and heating. "Taken as a whole, the results of these experiments, in particular the clarity of the images and ability to increase temperature with the same catheter, lead us to believe that the ultimate creation of a practical intracranial ultrasound catheter is possible," said Stephen Smith, director of the Duke University Ultrasound Transducer Group and senior member of the research team. "There are some design issues of the catheter itself that we feel can be overcome with little difficulty." Advances in ultrasound technology have made these latest experiments possible, the researchers said, by generating detailed, 3-D moving images in real-time. The Duke laboratory has a long track record of modifying traditional 2-D ultrasound - like that used to image babies in utero - into the more advanced 3-D scans. After inventing the technique in 1991, the team also has shown its utility in developing specialized catheters and endoscopes for real-time imaging of tissues throughout the body. Much of the liposome research was carried out at Duke by David Needham, professor of mechanical engineering and materials science, and Mark Dewhirst, professor of radiation oncology. Duke University |
|||||||||||||||||||||
| Related Chemotherapy Current Events and Chemotherapy News Articles First use of antibody and stem cell transplantation to successfully treat advanced leukemia For the first time, researchers at Fred Hutchinson Cancer Research Center have reported the use of a radiolabeled antibody to deliver targeted doses of radiation, followed by a stem cell transplant, to successfully treat a group of leukemia and pre-leukemia patients for whom there previously had been no other curative treatment options. New Synthetic Molecules Trigger Immune Response to HIV and Prostate Cancer Researchers at Yale University have developed synthetic molecules capable of enhancing the body's immune response to HIV and HIV-infected cells, as well as to prostate cancer cells. Their findings, published online in the Journal of the American Chemical Society, could lead to novel therapeutic approaches for these diseases. Chemo-radiation before prostate removal may prevent cancer recurrence Researchers in the Oregon Health & Science University Knight Cancer Institute and the Portland Veterans Affairs Medical Center have found a combination of radiation therapy and chemotherapy given before prostate removal is safe and may have the potential to reduce cancer recurrence and improve patient survival. PMH finding may help some tonsil cancer patients avoid chemotherapy Clinical researchers at Princess Margaret Hospital (PMH) have confirmed that patients with oropharyngeal squamous cell cancer ("tonsil cancer") harbour a common type of human papilloma virus (HPV16), but also that such cancers are very sensitive to radiation. Study of concurrent radiotherapy, chemotherapy shows promise in small cell lung cancer Treating limited stage small cell lung cancer(LSCL) with a combination of accelerated high-dose radiotherapy and chemotherapy has shown encouraging results. Blood vessels might predict prostate cancer behavior A diagnosis of prostate cancer raises the question for patients and their physicians as to how the tumor will behave. Will it grow quickly and aggressively and require continuous treatment, or slowly, allowing therapy and its risks to be safely delayed? Discovery offers potential new pancreatic cancer treatment Tiny particles that can carry drugs and target cancer cells may offer treatment hope for those suffering with pancreatic cancer. New research to be presented in November at the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting in Los Angeles reveals that tumor-penetrating microparticles (TPM) have been specifically designed to break through hard-to-infiltrate barriers and deliver drugs more effectively and efficiently than the standard form of chemotherapy such as those injected through a vein. Early-stage, HER2-positive breast cancer patients at increased risk of recurrence Early-stage breast cancer patients with HER2 positive tumors one centimeter or smaller are at significant risk of recurrence of their disease, compared to those with early-stage disease who do not express the aggressive protein, according to a study led by researchers at The University of Texas M. D. Anderson Cancer Center. An exquisite container In campy old movies, Lucretia Borgia swans around emptying powder from her ring into wine glasses carelessly left unattended. The poison ring is usually a confection of gold filigree holding a cabochon or faceted gemstone that can be broken to empty the ring's contents. It is invariably enormous - so large it is rather odd nobody seems to notice it. Duke develops nano-scale drug delivery for chemotherapy Going smaller could bring better results, especially when it comes to cancer-fighting drugs. More Chemotherapy Current Events and Chemotherapy News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||